- Patients
- Clinical Research
- Clinical trials
- Furmo-004
2023-07-10T00:00:00.000+01:00
Ongoing
Furmo-004
Furmo-004
Lung cancer
A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations
A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations
Trial overview
Clinical Area
Medical Oncology
Disease / Condition
Lung
Study Phase
III
Trial Identifiers
Registration number: NCT05607550 https://clinicaltrials.gov/study/NCT05607550
|
GenesisCare Location(s)
North Shore – Prof Nick Pavlakis
North Shore – Prof Nick Pavlakis
:::
Principal Investigator(s)
Prof Nick Pavlakis
Prof Nick Pavlakis
:::